Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
NKTR
Home
/
NKTR

NASDAQ
$38.48
$38.48

Overview

Price performance
Low
$37.50
High
$38.99
After hours. Last updated: Nov 4, 2026, 9:00 PM UTC
$
38.48
0.72 (1.91%)
Average, 50 days
$54.23
$65.02
Open
$38.74
Previous close
$37.76
52-week high
$109.00
Apr 20, 2026 (7 months ago)
52-week low
$33.40
Jan 30, 2026 (10 months ago)
15.21%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
1.10B
Volume
491 949
Total Return (3M)
-47.11%
Total Return (1Y)
-31.31%
—
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NASDAQ
US
Website
nektar.com
About
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.

Frequently asked questions

NKTR · Nektar Therapeutics

01What is Nektar Therapeutics stock price today?

The current price of NKTR is $38.48 — it has increased by 1.91% since the previous close. Data as of Nov 4, 2026.

02Is Nektar Therapeutics stock price growing?

NKTR is down 1.33% over the past week, down 11.70% over the past month and down 31.31% over the past year. The price is below its 200-day moving average of $65.02.

03What is Nektar Therapeutics market cap?

Nektar Therapeutics has a market capitalization of $1.1B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

04How volatile is NKTR stock?

In the latest trading session NKTR moved between $37.50 and $38.99, a range of 3.87% of its current price.

05What are NKTR stock 52-week high and low?

Over the past 52 weeks NKTR has traded between $33.40 and $109.00. The current price is 64.70% below its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.